{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:37:15Z","timestamp":1791430635969,"version":"4.3.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Autobahn Therapeutic","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Minoryx Therapeutics","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"SwanBio","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Adrenoleukodystrophy (ALD) is a rare, X-linked disease caused by pathogenic\n                      <jats:italic>ABCD1<\/jats:italic>\n                      gene variants, resulting in heterogeneous and debilitating conditions. We report on an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting involving patients and caregivers, Food and Drug Administration representatives, and physicians to hear the patient\u2019s voice regarding living with adult manifestations of ALD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with ALD and\/or caregivers were invited to the EL-PFDD to discuss the impact of living with ALD and their desires for future treatment\/management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>On July 22, 2022, the virtual EL-PFDD meeting took place with 254 individuals, including 153 adult patients with ALD and\/or caregivers. Men and women with ALD suffer from many health conditions with top concerns being balance issues (81%), altered gait (67%), and spasticity (67%). Disease impact on daily activities was significant; 69% had issues with walking, playing sports (45%), and sleeping (41%). Overall, 88% of respondents feared their condition worsening, being unable to walk (61%), and developing cerebral ALD (39%). There are no disease-specific treatments for adults; patients used various medications and physical therapies for symptom management, with either \u2018very little\u2019 (39% respondents) or \u2018somewhat\u2019 (44% respondents) of a response; 10% received no relief with treatments. In the future, patients want to be involved in treatment development and clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ALD is a progressive disease that can be life-limiting. There is an urgent need to develop treatments that will either slow, halt, or cure adult manifestations of ALD, and men and women are eager to be involved in studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04130-3","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:09:47Z","timestamp":1767870587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Living with adrenoleukodystrophy: adult patient and caregiver perspectives"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6855-8807","authenticated-orcid":false,"given":"Amena Smith","family":"Fine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen O\u2019","family":"Sullivan-Fortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Miettunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Sadjadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Fatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"9","key":"4130_CR1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.bbadis.2012.03.012","volume":"1822","author":"S Kemp","year":"2012","unstructured":"Kemp S, Berger J, Aubourg P. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta. 2012;1822(9):1465\u201374.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"4130_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jdn.10003","volume":"80","author":"BR Turk","year":"2020","unstructured":"Turk BR, Theda C, Fatemi A, Moser AB. X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020;80(1):52\u201372.","journal-title":"Int J Dev Neurosci"},{"issue":"1","key":"4130_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MED.0000000000000515","volume":"27","author":"L Eng","year":"2020","unstructured":"Eng L, Regelmann MO. Adrenoleukodystrophy in the era of newborn screening. Curr Opin Endocrinol Diabetes Obes. 2020;27(1):47\u201355.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"10","key":"4130_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrendo.2016.90","volume":"12","author":"S Kemp","year":"2016","unstructured":"Kemp S, Huffnagel IC, Linthorst GE, Wanders RJ, Engelen M. Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history. Nat Rev Endocrinol. 2016;12(10):606\u201315.","journal-title":"Nat Rev Endocrinol"},{"issue":"21","key":"4130_CR5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1212\/WNL.0000000000201374","volume":"99","author":"M Engelen","year":"2022","unstructured":"Engelen M, van Ballegoij WJC, Mallack EJ, Van Haren KP, Kohler W, Salsano E, et al. International recommendations for the diagnosis and management of patients with adrenoleukodystrophy: A Consensus-Based approach. Neurology. 2022;99(21):940\u201351.","journal-title":"Neurology"},{"issue":"1","key":"4130_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13023-024-03129-6","volume":"19","author":"A Varma","year":"2024","unstructured":"Varma A, Weinstein J, Seabury J, Rosero S, Dilek N, Heatwole J, et al. Patient-reported impact of symptoms in adrenoleukodystrophy (PRISM-ALD). Orphanet J Rare Dis. 2024;19(1):127.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4130_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13023-024-03276-w","volume":"19","author":"JL Bonkowsky","year":"2024","unstructured":"Bonkowsky JL, Healey B, Sacks NC, McLin R, Cyr PL, Sawyer EK, et al. Burden of illness and mortality in men with adrenomyeloneuropathy: a retrospective cohort study. Orphanet J Rare Dis. 2024;19(1):270.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"4130_CR8","doi-asserted-by":"publisher","first-page":"e2878","DOI":"10.1002\/brb3.2878","volume":"13","author":"L Schafer","year":"2023","unstructured":"Schafer L, Roicke H, Bergner CC, Kohler W. Self-reported quality of life in symptomatic and asymptomatic women with X-linked adrenoleukodystrophy. Brain Behav. 2023;13(3):e2878.","journal-title":"Brain Behav"},{"issue":"2","key":"4130_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/jimd.12044","volume":"42","author":"N Waldh\u00fcter","year":"2019","unstructured":"Waldh\u00fcter N, K\u00f6hler W, Hemmati PG, Jehn C, Peceny R, Vuong GL, et al. Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning for adult cerebral X-linked adrenoleukodystrophy. J Inherit Metab Dis. 2019;42(2):313\u201324.","journal-title":"J Inherit Metab Dis"},{"key":"4130_CR10","doi-asserted-by":"crossref","unstructured":"Golse M, Weinhofer I, Blanco B, Barbier M, Yazbeck E, Huiban C et al. Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy. Brain. 2024;147(10):3344\u201351.","DOI":"10.1093\/brain\/awae169"},{"issue":"1","key":"4130_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1210\/jc.2018-01307","volume":"104","author":"IC Huffnagel","year":"2019","unstructured":"Huffnagel IC, Laheji FK, Aziz-Bose R, Tritos NA, Marino R, Linthorst GE, et al. The natural history of adrenal insufficiency in X-Linked adrenoleukodystrophy: an international collaboration. J Clin Endocrinol Metab. 2019;104(1):118\u201326.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4130_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165\u201373.","journal-title":"Eur J Hum Genet"},{"key":"4130_CR13","unstructured":"European Commission. Rare diseases: EU research on rare diseases [Available from: https:\/\/research-and-innovation.ec.europa.eu\/research-area\/health\/rare-diseases_en"},{"key":"4130_CR14","unstructured":"Food and Drug Administration. 2022 [Available from: https:\/\/www.fda.gov\/science-research\/focus-areas-regulatory-science-report\/cross-cutting-topics-rare-diseases-regulatory-science-research#:~:text=A%20rare%20disease%20is%20defined,recovery%20provisions%20of%20the%20act"},{"issue":"4","key":"4130_CR15","first-page":"3","volume":"8","author":"A Fehr","year":"2023","unstructured":"Fehr A, Prutz F. Rare diseases: a challenge for medicine and public health. J Health Monit. 2023;8(4):3\u20136.","journal-title":"J Health Monit"},{"issue":"7","key":"4130_CR16","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(24)00134-7","volume":"12","author":"G Baynam","year":"2024","unstructured":"Baynam G, Hartman AL, Letinturier MCV, Bolz-Johnson M, Carrion P, Grady AC, et al. Global health for rare diseases through primary care. Lancet Glob Health. 2024;12(7):e1192\u20139.","journal-title":"Lancet Glob Health"},{"key":"4130_CR17","unstructured":"Food and Drug Administration. Externally-led patient-focused drug development meetings 2022 [Available from: https:\/\/www.fda.gov\/industry\/prescription-drug-user-fee-amendments\/externally-led-patient-focused-drug-development-meetings"},{"issue":"10","key":"4130_CR18","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrg3555","volume":"14","author":"KM Boycott","year":"2013","unstructured":"Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14(10):681\u201391.","journal-title":"Nat Rev Genet"},{"key":"4130_CR19","unstructured":"Global Genes. RARE disease facts: Global Genes; 2023 [Available from: https:\/\/globalgenes.org\/learn\/rare-disease-facts\/"},{"key":"4130_CR20","doi-asserted-by":"publisher","first-page":"1309053","DOI":"10.3389\/fendo.2023.1309053","volume":"14","author":"M Cappa","year":"2023","unstructured":"Cappa M, Todisco T, Bizzarri C. X-linked adrenoleukodystrophy and primary adrenal insufficiency. Front Endocrinol (Lausanne). 2023;14:1309053.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"4130_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/1531-8249(20010201)49:2<186::AID-ANA38>3.0.CO;2-R","volume":"49","author":"BM van Geel","year":"2001","unstructured":"van Geel BM, Bezman L, Loes DJ, Moser HW, Raymond GV. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol. 2001;49(2):186\u201394.","journal-title":"Ann Neurol"},{"issue":"Pt 3","key":"4130_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/brain\/awt361","volume":"137","author":"M Engelen","year":"2014","unstructured":"Engelen M, Barbier M, Dijkstra IM, Sch\u00fcr R, de Bie RM, Verhamme C, et al. X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. Brain. 2014;137(Pt 3):693\u2013706.","journal-title":"Brain"},{"key":"4130_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1750-1172-9-6","volume":"9","author":"CT Habekost","year":"2014","unstructured":"Habekost CT, Schestatsky P, Torres VF, de Coelho DM, Vargas CR, Torrez V, et al. Neurological impairment among heterozygote women for X-linked adrenoleukodystrophy: a case control study on a clinical, neurophysiological and biochemical characteristics. Orphanet J Rare Dis. 2014;9:6.","journal-title":"Orphanet J Rare Dis"},{"issue":"7\u2013b Suppl","key":"4130_CR24","first-page":"S1","volume":"30","author":"T Richardson","year":"2024","unstructured":"Richardson T, Rice M, Lyon ME, Kobernick M, Brackbill L. Impact of mental health in persons living with rare disease: findings from the AMCP market insights program. J Manag Care Spec Pharm. 2024;30(7\u2013b Suppl):S1\u201311.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"4130_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10826-024-02790-6","volume":"33","author":"JC Atkins","year":"2024","unstructured":"Atkins JC, Padgett CR. Living with a rare disease: psychosocial impacts for parents and family Members \u2013 a systematic review. J Child Fam Stud. 2024;33(2):617\u201336.","journal-title":"J Child Fam Stud"},{"issue":"4","key":"4130_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/01.gim.0000215177.28010.6e","volume":"8","author":"CA James","year":"2006","unstructured":"James CA, Hadley DW, Holtzman NA, Winkelstein JA. How does the mode of inheritance of a genetic condition influence families? A study of guilt, blame, stigma, and Understanding of inheritance and reproductive risks in families with X-linked and autosomal recessive diseases. Genet Med. 2006;8(4):234\u201342.","journal-title":"Genet Med"},{"issue":"3","key":"4130_CR27","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2214-109X(24)00056-1","volume":"12","author":"The Lancet Global Health","year":"2024","unstructured":"The Lancet Global Health. The landscape for rare diseases in 2024. Lancet Glob Health. 2024;12(3):e341.","journal-title":"Lancet Glob Health"},{"issue":"8","key":"4130_CR28","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1038\/s41591-023-02333-4","volume":"29","author":"M May","year":"2023","unstructured":"May M. Rare-disease researchers pioneer a unique approach to clinical trials. Nat Med. 2023;29(8):1884\u20136.","journal-title":"Nat Med"},{"issue":"10","key":"4130_CR29","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1093\/brain\/awae169","volume":"147","author":"M Golse","year":"2024","unstructured":"Golse M, Weinhofer I, Blanco B, Barbier M, Yazbeck E, Huiban C, et al. Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy. Brain. 2024;147(10):3344\u201351.","journal-title":"Brain"},{"issue":"2","key":"4130_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1474-4422(22)00495-1","volume":"22","author":"W K\u00f6hler","year":"2023","unstructured":"K\u00f6hler W, Engelen M, Eichler F, Lachmann R, Fatemi A, Sampson J, et al. Safety and efficacy of Leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2\u20133 trial. Lancet Neurol. 2023;22(2):127\u201336.","journal-title":"Lancet Neurol"},{"key":"4130_CR31","unstructured":"Food and Drug Administration. SKYSONA 2024 [updated October 4. 2024. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/skysona"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04130-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04130-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04130-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:18:48Z","timestamp":1781626728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04130-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4130"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04130-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not needed for this study. Participants were invited to share comments that they were informed would be made publicly available as part of the EL-PFDD. Meeting pre-recordings, live-speaking during the EL-PFDD, and participation in the meeting (submission of comments and participation in polling questions) were entirely voluntary and implied consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Attendance and involvement in the EL-PFDD was entirely voluntary, with attendees being informed that the outcome of the meeting would be made publicly available. As a result, consent for publication was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ASF, KM, FE, and RS have no conflicts of interest to disclose. AF, FEi, and KOSF are Co-Founders of ALD Connect. AF has received research funding as the site PI for clinical trials sponsored by Minoryx and Viking Therapeutics; is an institutional consultant for Vertex, Autobahn Therapeutics, Poxel Therapeutics, Sanofi, Spolia Therapeutics, Vigil Neuroscience, Takeda, SwanBio; and has served as a paid DSMB member for bluebird bio (now Genetix Biotherapeutics). FEi was a PI for ASPA Therapeutics; a co-PI for bluebird bio, Sio Therapeutics and UMASS Chan Medical School; a site PI for Ionis Pharmaceuticals and the n-Lorem Foundation; a consultant to Atlas Venture, Acadia Pharmaceuticals, Leal Therapeutics, Orchard Therapeutics, Sanofi Pharmaceuticals, Spolia Therapeutics, Spur Therapeutics, Takeda Therapeutics, UpToDate, and Vigil Neuro; and the Founder of SwanBio Therapeutics (now Spur Therapeutics).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"8"}}